Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial

Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment

(2011) M. Nowicki et al.   DIABETES OBESITY & METABOLISM

Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans

(2011) B. Ahrén et al.   DIABETES OBESITY & METABOLISM

An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials

(2010) M. Ligueros-Saylan et al.   DIABETES OBESITY & METABOLISM

Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population

(2010) A. Schweizer et al.   DIABETES OBESITY & METABOLISM

Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials

(2010) A. Schweizer et al.   DIABETES OBESITY & METABOLISM

Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: A retrospective analysis of the GALIANT study

(2010) M.A. Banerji et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus

(2010) Joshua J Neumiller et al.   PHARMACOTHERAPY

Management of diabetes in dialysis patients

(2009) Mark E. Williams   Current Diabetes Reports

Vildagliptin Enhances Islet Responsiveness to Both Hyper- and Hypoglycemia in Patients with Type 2 Diabetes

(2009) Bo Ahrén et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea*

(2008) A. J. Garber et al.   DIABETES OBESITY & METABOLISM

Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency

(2008) J. C. N. Chan et al.   DIABETES OBESITY & METABOLISM

Absorption, Metabolism, and Excretion of [14C]Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Humans

(2008) H. He et al.   DRUG METABOLISM AND DISPOSITION

Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis

(2008) Debora Williams-Herman et al.   BMC Endocrine Disorders